article thumbnail

BioSig abandons COVID-19 drug trial on safety concerns

pharmaphorum

US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. Merimepodib is the subsidiary’s primary asset, and the biotech now says it is to offers to acquire or license the drug.

article thumbnail

Leading clinical packaging companies in contract marketing

Pharmaceutical Technology

Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers. Clinical trial packaging and labelling solutions.

Packaging 100